|Day Low/High||17.95 / 18.17|
|52 Wk Low/High||14.61 / 22.21|
Jim Cramer's charitable trust closed out its position in AbbVie on Tuesday, citing concerns for its 'expensive' acquisition plans for Pharmacylics.
European stock indices were mixed on Thursday, with core eurozone indices helped by a bigger-than-expected decline in German joblessness amid earnings reports from some of the region's largest companies.
Several European conglomerates, especially in the healthcare and pharmaceutical sectors, benefit from a weak Euro.
Bayer (BAYRY) plans to list its less profitable plastics business on the stock market in a deal that could value the division at about $13 billion.
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.
Pfizer's hard-fought control of the erectile dysfunction drug market in China is about to end, cheering its local rivals
Merck (MRK) shares are down in pre-market trading after being downgraded to 'equalweight' by analysts at Morgan Stanley (MS) today.
Shares of Merck (MRK) are higher after the company announced that it entered into a definitive agreement to sell its Merck Consumer Care business to Bayer (BAYRY) for $14.2 billion.
Shares of Reckitt Benckiser (RBGLY) are down after the company said it's no longer in active talks to buy the consumer health unit of Merck & Co. (MRK), although Bayer (BAYRY) has proposed a deal.
Shares of Bayer (BAYRY) are higher after it was reported that the pharmaceutical and chemicals company is exploring a sale of its $10 billion plastics unit to focus on expanding the health business.
Shareholders were rewarded with a return of 65%. They should now consider investing in acquirer Amgen. Here's why.
The offer to pay for a 'next-generation' toilet comes as China grapples with its fast-growing cities and their waste.
Tie-up could bring $540 million for Compugen's cancer immunotherapy treatments.
The FDA has let down renal cancer patients with its Tivozanib decision.
The nation's pollution worsened with the incessant explosion of New Year's fireworks, despite what officials say.
Francis Gaskins, president of IPO Desktop, says he's going to sit on the sidelines with KYTHERA and Intercept.
Emerging markets' demand, coupled with healthy dividends, boost drugmakers.
Sponsorships from Viagra, Cialis and Levitra make some players cringe when they should be grateful.
Err on the side of caution when it comes to chemicals in food, drinks, toys and other products.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.